Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2003-04-04
2011-11-08
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S350000
Reexamination Certificate
active
08053551
ABSTRACT:
Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
REFERENCES:
patent: 4867973 (1989-09-01), Goers et al.
patent: 5001225 (1991-03-01), Taylor
patent: 5571894 (1996-11-01), Wels et al.
patent: 6048970 (2000-04-01), Lal et al.
patent: 6329503 (2001-12-01), Afar et al.
patent: 6833438 (2004-12-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0146692 (2002-10-01), Yamazaki et al.
patent: 2002/0192763 (2002-12-01), Xu et al.
patent: 2003/0045682 (2003-03-01), Afar et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 2003/0100540 (2003-05-01), Zhang et al.
patent: 2004/0005598 (2004-01-01), DeVaux et al.
patent: 2002-517184 (2002-02-01), None
patent: WO 94/09150 (1994-04-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO9853071 (1998-11-01), None
patent: WO9906548 (1999-02-01), None
patent: WO9906550 (1999-02-01), None
patent: WO9962941 (1999-12-01), None
patent: WO0004149 (2000-01-01), None
patent: WO 00/35937 (2000-06-01), None
patent: WO0077021 (2000-12-01), None
patent: WO 01/08636 (2001-02-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO0125272 (2001-04-01), None
patent: WO0134802 (2001-05-01), None
patent: WO 01/42270 (2001-06-01), None
patent: WO 01/45728 (2001-06-01), None
patent: WO0140276 (2001-06-01), None
patent: WO0151633 (2001-07-01), None
patent: WO0157190 (2001-08-01), None
patent: WO0157273 (2001-08-01), None
patent: WO0157276 (2001-08-01), None
patent: WO0157277 (2001-08-01), None
patent: WO0160860 (2001-08-01), None
patent: WO0170979 (2001-09-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO0173032 (2001-10-01), None
patent: WO0175067 (2001-10-01), None
patent: WO0186003 (2001-11-01), None
patent: WO0194629 (2001-12-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO0230268 (2002-04-01), None
patent: WO02077013 (2002-10-01), None
patent: WO02077186 (2002-10-01), None
patent: WO02089747 (2002-11-01), None
patent: WO02092787 (2002-11-01), None
patent: WO03004623 (2003-01-01), None
patent: WO03009814 (2003-02-01), None
patent: WO03022995 (2003-03-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 03/022995 (2006-03-01), None
patent: WO 2006/034488 (2006-03-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990.
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Brennan et al (Journal of Autoimmunity, 1989, vol. 2 suppl., pp. 177-186).
Zimmer (Cell Motility and the Cytoskeleton, 1991, vol. 20, pp. 325-337).
Eriksson et al. (Diabetologia, 1992, vol. 35, pp. 143-147).
Hubert et al., Dec. 7, 1999, PNAS vol. 96, pp. 14523-14528.
Bowie et al, Science, 1990, 257:1306-1310.
Burgess et al, J of Cell Bio. 111:2129-2138, 1990.
Lazar et al, Molecular and Cellular Biology, 1988, 8:1247-1252.
DATABASE GENEMBL, Accession No. AC003991, XP002173859, Pub Date: Jun. 17, 1998, R. Waterston et al.
Challita-Eid Pia M., et al., “Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo”, vol. 67, No. 12, pp. 5798-5805, (2007).
Faris M., et al., “Validation of STEAP-1 as a cell surface cancer therapeutic target”, Proceedings of the annual meeting of the American Association for Cancer Research, vol. 43, p. 947, (2002).
Abaza, et al., “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide Immunization: Demonstrated with region 94-100 (antigenic Site 3) of myoglobin”, Journal of Protein Chemistry, vol. 11, No. 5, pp. 433-444, (1992).
Boon, Adv. Can. Res., 58: 177-210, (1992).
Coleman, “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immunology, 145(1): 33-36, (1994).
Cruse, et al., (Illustrated Dictionary of Immunology, CRC Press, New york, pp. 241, 1995).
Dillman, “Monoclonal antibodies for treating cancer”, Annals of Internal Medicine, 111: 592-603, (1989).
Dorland's Illustrated Medical Dictionary 26thed. (W.B. Saunders Co. Philadelphia, 1985, p. 1193).
Ezzell, J. NIH Res., 7: 46-49, (1995).
Greenbaum, et al., “Comparing protein abundance and mRNA expression levels on a genomic scale”, Genome Biology, vol. 4, Issue 9, pp. 117.1-117.8, (2003).
Greenspan, et al., “Defining epitopes: It's not as easy as it seems”, Nature Biotechnology, 7: 936-937, (1999).
Gura, et al., Science, 278: 1041-1042, (1997).
Harlow, et al., Antibodies, a laboratory manual, Cold spring harbor Laboratory Press, Ch. 5, pp. 76, (1988).
Hell, et al., “hodgkin cells accumulate mRNA for bcl-2”, Laboratory Investigation, vol. 73, No. 4, pp. 492-496, (1995).
Holmes, “PSMA specific antibodies and their diagnostic and therapeutic use”, Exp. Opin. Invest. Drugs, 10(3): 511-519, (2001).
Jang, et al., “An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells”, Clinical and Experimental Metastasis, vol. 15. No. 5, pp. 469-483, (1997).
Kirkin, et al., APMIS, 106: 665-679, (1998).
McClean, et al., Eur. J. of cancer, vol. 29A, pp. 2243-2248, (1993).
Roitt, et al., Immunology, 4thed, 1998.
Shantz and Pegg, Int. J. of Biochem. and cell Biol., vol. 31, pp. 107-122, (1999).
Spitler, Cancer Biotherapy, 10: 1-3, (1995).
Tanaka, et al., “Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens”, PNAS, vol. 82, pp. 3400-3404, (1985).
Vallejo, et al., “Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression”, Biochimie, 82: 1129-1133, (2000).
Voet, et al., Biochemistry, pp. 1095-1099, (1990).
White, et al., Ann. Rev. Med., 52: 125-145, (2001).
International Search Report mailed on Apr. 28, 2003, for PCT patent application No. PCT/US02/28371 filed on Sep. 6, 2002, 1 page.
Afar Daniel E.
Hubert Rene S.
Mitchell Stephen Chappell
Raitano Arthur B.
Saffran Douglas C.
Agensys, Inc.
Dreger Ginger R.
Halvorson Mark
Pasqualone Danielle
Popp Shane M.
LandOfFree
Serpentine transmembrane antigens expressed in human cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serpentine transmembrane antigens expressed in human cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serpentine transmembrane antigens expressed in human cancers... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263124